Targeted, anti-clotting meds had less risk of major bleeding for rare, deadly strokes

Research Highlights:

  • In an international, retrospective analysis of  direct oral anti-clotting medications that target a single clotting factor worked just as well to prevent future clots as the older, less-specific medication warfarin, and were less likely to result in major bleeding.
  • A cerebral venous thrombosis stroke is rare yet potentially life-threatening and is more common than other types of strokes among younger adults and women.
  • Treatment for cerebral venous thrombosis includes direct oral anti-clotting medications.

Embargoed until 11:28 a.m. CT/12:28 p.m. ET Thursday, Feb. 10, 2022

(NewMediaWire) – February 10, 2022 – NEW ORLEANS – Direct oral anti-coagulant (anti-clotting) (DOAC) medications that target a single clotting factor work just as well to prevent future clots as the older, less-specific medication warfarin. DOACs are also less likely to result in major bleeding after a rare, life threatening stroke involving a clot blocking one of the veins that drains blood from the brain, according to preliminary late-breaking science presented today at the American Stroke Association’s International Stroke Conference 2022, a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health to be held in person in New Orleans and virtually, Feb. 9-11, 2022.

A cerebral venous thrombosis (CVT) stroke is rare, yet potentially life-threatening and is more common than other types of strokes among younger adults and women.

“Taking birth control pills and recent childbirth are two big risk factors for CVT, so that’s likely why CVT is more common among women,” said Shadi Yaghi, M.D., lead author of the study, an associate professor of neurology and the vascular neurology division chief at The Warren Alpert Medical School of Brown University in Providence, Rhode Island.

When CVT is diagnosed, the immediate standard treatment includes administering intravenous or injectable anticoagulants, such as enoxaparin or heparin, to dissolve the clot and restore blood drainage. Later, oral anti-clotting medications are prescribed to prevent another clot from forming so there can be sustained, adequate blood flow through the veins. If a temporary factor (such as birth control pills or recent childbirth) is thought to have provoked the CVT, oral anti-clotting medications are commonly prescribed for several months. If the patient has a lifelong major medical condition that increases the risk of recurrent clots, anti-clotting medications are usually prescribed indefinitely.

Newer and more specific anti-clotting medications, called DOACs, have previously been compared to warfarin for treating several other conditions, including atrial fibrillation (a common arrhythmia that is a major risk factor for clot-caused strokes), and leg and lung clots. DOACs have been found to work just as well at preventing recurrent clots with a lower chance of the serious adverse effect of brain bleeding. After a small, randomized trial suggested that one DOAC called dabigatran may be as effective as warfarin after a CVT, the researchers conducted a multi-center review comparing six years of real-world experience using warfarin or any of the DOACs for patients with CVT.

The researchers examined the medical records for 1,025 people treated for CVT between 2015 and 2020 at one of 27 centers in the United States, Europe and New Zealand. For the analysis, patients were excluded if they had cancer, an antiphospholipid antibody syndrome (an acquired condition that raises clotting risk) or were not prescribed oral anticoagulants.

Of the 845 participants in the final analysis (average age of 44.8 years; 64.7% women), 33% were prescribed a DOAC only; 51.8% were prescribed warfarin only; and 15.1% were prescribed both treatments, at different times.

During a median follow-up time of 345 days, the researchers calculated that, for every 100 patient-years, there were 5.68 recurrent venous blood clots, 3.77 major hemorrhages and 1.84 deaths. When compared to participants treated with warfarin, participants treated with DOACs had:

  • a similar risk of recurrent vein clots and death, and
  • a 65% lower risk of major bleeding anywhere in the body.

When examined separately, the occurrence of brain bleeds per 100 patient-years was much lower among the patients prescribed DOACs than those who were prescribed warfarin (1.52 vs. 3.51, respectively), while the occurrence of major bleeding outside the brain was similar (0.91 vs. 1.15, respectively).

Imaging of the areas involved in the CVT were compared between the two treatment types for 525 participants, which excluded those who had their blood clots surgically treated, those who had no follow-up imaging after starting on oral anticoagulant and those who already had adequate blood flow through their veins prior to starting on oral anticoagulants. The analysis found that among the participants prescribed DOACs:

  • veins were completely open for 36.6% of participants, partially open for 48.2% and remained closed in 15.2%; and
  • they were just as likely to have achieved partially or fully opened veins compared to the participants prescribed warfarin.

Results were adjusted for age, sex and relevant medical conditions.

“These findings using real-world data suggest that direct oral anticoagulants are equally as effective as warfarin in reducing the chance of recurrent blood clots and increasing the chance of recanalization (dissolving of the clot either completely or partially leading to opening of the vein), and they have a lower risk of major bleeding,” said Yaghi, who is also co-director of the comprehensive stroke center at Rhode Island Hospital in Providence. “For treating CVT patients, both DOACS and warfarin are reasonable options, particularly since even with warfarin, the risk of bleeding is rather low.”

The study’s limitations include being a retrospective analysis, so the authors state that the findings should be interpreted with caution pending confirmation by large, ongoing, prospective or randomized studies.

Study co-authors are Liqi Shu, M.D.; Ekaterina Bakradze, M.D.; Setareh Salehi Omran, M.D.; James A. Giles, M.D.; Jordan Y. Amar, M.D.; Nils Henninger, M.D.; Marwa Elnazeir, M.D.; Ava L. Liberman, M.D.; Khadean Moncrieffe, B.S.; Jenny Lu, B.S.; Richa Sharma, M.D., Yee Cheng, M.D.; Adeel S. Zubair, M.D.; Alexis N. Simpkins, M.D.; Grace T. Li, M.D.; Justin Chi Kung, B.S.; Dezaray Perez, B.S.; Mirjam Heldner, M.D., Adrian Scutelnic, M.D.; David Seiffge, M.D.; Bernhard Siepen, M.D.; Aaron Rothstein, M.D.; Ossama Khazaal, M.D.; David Do, M.D.; Sami Al Kasab, M.D.; Line Abdul Rahman, M.D.; Eva A. Mistry, M.D.; Deborah Kerrigan, M.D.; Hayden Lafever, B.S.; Thanh N. Nguyen, M.D.; Piers Klein, B.S.; Hugo Aparicio, M.D.; Jennifer Frontera, M.D.; Lindsey Kuohn, B.S.; Shashank Agarwal, M.D.; Christoph Stretz, M.D.; Narendra Kala, M.D.; Sleiman El Jamal, M.D.; Alison Chang, B.S.; Shawna Cutting, M.D.; Han Xiao, M.P.H.; Adam de Havenon, M.D.; Varsha Muddasani, M.D.; Teddy Wu, M.D.; Duncan Wilson, M.D.; Amre Nouh, M.D.; Syed Daniyal Assad, M.D.; Abid Qureshi, M.D.; Justin Moore, M.D.; Pooja Khatri, M.D.; Yasmin Aziz, M.D.; Bryce Casteigne, M.D.; Muhib Khan, M.D.; Yao Cheng, M.D.; Brian Mac Grory, M.D.; Martin Weiss, M.D.; Dylan Ryan, M.D.; Maria Cristina Vedovati, M.D.; Maurizio Paciaroni, M.D.; James E. Siegler, M.D.; Scott Kamen, B.S.; Siyuan Yu, B.S.; Christopher R. Leon Guerrero, M.D.; Eugenie Atallah, M.D.; Gian Marco De Marchis, M.D.; Alex Brehm, M.D.; Tolga Dittrich, M.D.; Marios Psychogios, M.D.; Ronald Alvarado-Dyer, M.D.; Tareq Kass-Hout, M.D.; Shyam Prabhakaran, M.D.; Tristan Honda, B.S.; David S. Liebeskind, M.D.; and Karen Furie, M.D. The list of authors’ disclosures is available in the abstract.

The study was partially supported by the Italian Ministry of Health Ricerca Corrente – IRCCS MultiMedica.

Statements and conclusions of studies that are presented at the American Stroke Association and American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

Additional Resources:

The American Stroke Association’s International Stroke Conference (ISC) is the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease. ISC 2022 will be held in person in New Orleans and virtually, Feb. 9-11, 2022. The three-day conference will feature more than 1,500 compelling presentations in 17 categories that emphasize basic, clinical and translational sciences as research evolves toward a better understanding of stroke pathophysiology with the goal of developing more effective therapies. Engage in the International Stroke Conference on social media via #ISC22.

About the American Stroke Association

The American Stroke Association is devoted to saving people from stroke — the No. 2 cause of death in the world and a leading cause of serious disability. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat stroke. The Dallas-based association officially launched in 1998 as a division of the American Heart Association. Connect with us on, Facebook, Twitter or by calling 1-888-4STROKE.


For Media Inquiries and AHA Expert Perspective:

AHA Communications & Media Relations in Dallas: 214-706-1173;

Karen Astle: 214-706-1392;

For Public Inquiries: 1-800-AHA-USA1 (242-8721) and